MAPT and Alzheimer disease: The development of drugs for the treatment of AD has been made difficult not only due to impermeability of drugs into the brain via the BBB [9], but also due to the complex mechanisms of AD pathogenesis, wherein the pathological mechanisms of Aβ and tau are known to play crucial roles.